Great investor presentation (again).
Interesting to note the parameters and subs aspired by our imminent breastcancer phase 1 complete data sets.
ORR >25%, and pCR>16% (11-22).
May be worth a re-visit to the 1b top line results for some (encouraging indeed).
Also, would like to know the progress of the ptx-100 orphan drug application.
As our CEO stated’ multiple shots at goal’.
Luck to all holders.
Ann: March 2018 Investor Presentation, page-2
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $30.60M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.8¢ | $47.91K | 1.256M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 881755 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 150000 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PTX (ASX) Chart |